QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE

Daniel P Morin1, Lasse Oikarinen, Matti Viitasalo

  • 1Division of Cardiology, Ochsner Clinic Foundation, New Orleans, LA, USA.

European Heart Journal
|August 19, 2009
PubMed

Insights

Prolonged QRS duration independently predicts sudden cardiac death (SCD) in treated hypertensive patients with left ventricular hypertrophy (LVH). This finding holds true even when accounting for other risk factors and treatment changes.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Electrocardiography

Background:

  • Left ventricular hypertrophy (LVH) and hypertension are significant risk factors for cardiovascular events.
  • Sudden cardiac death (SCD) remains a major concern in managing hypertensive patients.

Purpose of the Study:

  • To investigate if QRS duration predicts SCD in hypertensive patients with LVH.
  • To assess the predictive value of QRS duration beyond established risk factors.

Main Methods:

  • Analysis of 9193 hypertensive patients with electrocardiographic evidence of LVH.
  • Follow-up over 4.8 years, monitoring for SCD.
  • Multivariable analysis including treatment, blood pressure changes, and baseline characteristics.

Main Results:

  • 178 patients (1.9%) experienced SCD.
  • QRS duration was an independent predictor of SCD (HR per 10 ms increase = 1.22, P < 0.001).
  • QRS duration remained significant after controlling for left bundle branch block and LVH severity changes.

Conclusions:

  • Prolonged QRS duration identifies hypertensive patients at increased risk for SCD.
  • This risk is present even with aggressive antihypertensive therapy and LVH treatment.
  • QRS duration is a valuable prognostic marker in this patient population.
Abstract

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Dysrhythmias V: Evaluating Dysrhythmias01:30

Dysrhythmias V: Evaluating Dysrhythmias

Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...